Letter to Editor
BibTex RIS Cite

IS SERONEGATIVE SJÖGREN'S SYNDROME: AN OVERLOOKED ENTITY?

Year 2024, Volume: 5 Issue: 1, 34 - 36, 28.03.2024

Abstract

Primary Sjögren syndrome (pSS) is a systemic autoimmune disorder characterized by the chronic inflammation and dysfunction of exocrine glands, mainly salivary glands, causing dryness of the eyes and the mouth. Patients present with a spectrum of clinical manifestations from sicca (dryness) symptoms to potentially severe extra glandular and/or systemic features, such as inflammatory arthritis, parotitis, interstitial lung disease, neurological dysfunction, cryoglobulinemia, and lymphomas. SS have autoantibodies such as anti-Ro/SSA, anti-La/SSB, antinuclear antibodies (ANA), and rheumatoid factors(RF). These autoantibodies are present in 45% to 75% of patients. Patients fulfilling SS criteria who do not express classic serum antibodies are called patients with seronegative SS. Seronegative SS varies in the literature, ranging from 8% to 37% of SS cohorts. Diagnosing seronegative pSS can be difficult. Without readily detectable serum biomarkers, patients with seronegative SS may be overlooked in the clinic. Here we present 3 cases of seronegative SS with different organ involvement.

SERONEGATIVE SJÖGREN SENDROMU: GÖZDEN KAÇAN BIR ANTITE MI?

Year 2024, Volume: 5 Issue: 1, 34 - 36, 28.03.2024

Abstract

Primary Sjögren syndrome (pSS) is a systemic autoimmune disorder characterized by the chronic inflammation and dysfunction of exocrine glands, mainly salivary glands, causing dryness of the eyes and the mouth. Patients present with a spectrum of clinical manifestations from sicca (dryness) symptoms to potentially severe extra glandular and/or systemic features, such as inflammatory arthritis, parotitis, interstitial lung disease, neurological dysfunction, cryoglobulinemia, and lymphomas. SS have autoantibodies such as anti-Ro/SSA, anti-La/SSB, antinuclear antibodies (ANA), and rheumatoid factors(RF). These autoantibodies are present in 45% to 75% of patients. Patients fulfilling SS criteria who do not express classic serum antibodies are called patients with seronegative SS. Seronegative SS varies in the literature, ranging from 8% to 37% of SS cohorts. Diagnosing seronegative pSS can be difficult. Without readily detectable serum biomarkers, patients with seronegative SS may be overlooked in the clinic. Here we present 3 cases of seronegative SS with different organ involvement.

There are 0 citations in total.

Details

Primary Language English
Subjects Rheumatology and Arthritis
Journal Section Letter to the Editor
Authors

Erdal Bodakçi 0000-0002-0402-1525

Esra Erpek 0000-0003-3540-4905

Early Pub Date March 28, 2024
Publication Date March 28, 2024
Submission Date January 30, 2024
Acceptance Date February 22, 2024
Published in Issue Year 2024 Volume: 5 Issue: 1

Cite

APA Bodakçi, E., & Erpek, E. (2024). IS SERONEGATIVE SJÖGREN’S SYNDROME: AN OVERLOOKED ENTITY?. Eskisehir Medical Journal, 5(1), 34-36.
AMA Bodakçi E, Erpek E. IS SERONEGATIVE SJÖGREN’S SYNDROME: AN OVERLOOKED ENTITY?. Eskisehir Med J. March 2024;5(1):34-36.
Chicago Bodakçi, Erdal, and Esra Erpek. “IS SERONEGATIVE SJÖGREN’S SYNDROME: AN OVERLOOKED ENTITY?”. Eskisehir Medical Journal 5, no. 1 (March 2024): 34-36.
EndNote Bodakçi E, Erpek E (March 1, 2024) IS SERONEGATIVE SJÖGREN’S SYNDROME: AN OVERLOOKED ENTITY?. Eskisehir Medical Journal 5 1 34–36.
IEEE E. Bodakçi and E. Erpek, “IS SERONEGATIVE SJÖGREN’S SYNDROME: AN OVERLOOKED ENTITY?”, Eskisehir Med J, vol. 5, no. 1, pp. 34–36, 2024.
ISNAD Bodakçi, Erdal - Erpek, Esra. “IS SERONEGATIVE SJÖGREN’S SYNDROME: AN OVERLOOKED ENTITY?”. Eskisehir Medical Journal 5/1 (March 2024), 34-36.
JAMA Bodakçi E, Erpek E. IS SERONEGATIVE SJÖGREN’S SYNDROME: AN OVERLOOKED ENTITY?. Eskisehir Med J. 2024;5:34–36.
MLA Bodakçi, Erdal and Esra Erpek. “IS SERONEGATIVE SJÖGREN’S SYNDROME: AN OVERLOOKED ENTITY?”. Eskisehir Medical Journal, vol. 5, no. 1, 2024, pp. 34-36.
Vancouver Bodakçi E, Erpek E. IS SERONEGATIVE SJÖGREN’S SYNDROME: AN OVERLOOKED ENTITY?. Eskisehir Med J. 2024;5(1):34-6.